ContraVir Pharmaceuticals (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the results of a Phase 1 study with TXL™ assessing the safety, pharmacokinetics and tolerability of TXL™ in patients with severe renal impairment.

As quoted in the press release:

Importantly, the data showed that the blood concentrations of tenofovir (TFV) in severely renally-impaired subjects receiving 50 mg of TXL™ were similar to the TFV exposure levels observed after dosing of Viread® 300 mg, the current standard of care. These findings indicate that dosing strength adjustments of TXL™ is not warranted in patients with compromised renal function.

Click here to read the full press release.